Selenium(Selenium) - 药物靶点：survivin_在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

selenium、Selenase

靶点

survivin

作用方式

抑制剂

作用机制

survivin抑制剂(杆状病毒IAP重复包含蛋白-5抑制剂)

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症

获得性免疫缺陷综合征脑损伤心脏毒性+ [15]

原研机构-

在研机构

Roswell Park Comprehensive Cancer Center

非在研机构

biosyn Corp.

Fundação Oswaldo Cruz

Boryung Corp.

+ [1]

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

214

项与 Selenium 相关的临床试验

NCT07334197

/ Not yet recruitingN/AIIT

Effect of Melatonin in Peripartum Cardiomyopathy

This randomized, controlled clinical trial investigates the potential cardioprotective effects of melatonin in women diagnosed with peripartum cardiomyopathy (PPCM). The study aims to determine whether melatonin supplementation improves left ventricular (LV) function, promotes reverse remodeling, and reduces systemic inflammation. Participants receive standardized heart failure therapy with or without adjunctive melatonin, and outcomes are assessed using echocardiographic parameters (including LVEF, LV dimensions, and global longitudinal strain) and inflammatory biomarkers (e.g., CRP, IL-6, TNF-α). The study hypothesizes that melatonin's antioxidant and anti-inflammatory properties will enhance cardiac recovery, improve functional capacity, and potentially reduce morbidity in PPCM patients.

开始日期2026-12-20

申办/合作机构

Tanta University

[+1]

IRCT20251109067930N1

/ Suspended临床2/3期IIT

Studying the effect of oral selenium on the size of non-malignant thyroid nodules

开始日期2025-12-21

申办/合作机构-

CTRI/2025/12/098593

/ Not yet recruiting临床2期IIT

Selenium as an adjunctive therapy in patients with Schizophrenia : An MRS-Based open Label Study - NIL

开始日期2025-12-19

申办/合作机构-

100 项与 Selenium 相关的临床结果

登录后查看更多信息

100 项与 Selenium 相关的转化医学

登录后查看更多信息

100 项与 Selenium 相关的专利（医药）

登录后查看更多信息

12,798

项与 Selenium 相关的文献（医药）

2026-12-31·Journal of the International Society of Sports Nutrition

International Society of Sports Nutrition position stand: effects of dietary antioxidants on exercise and sports performance

Review

作者: Dickerson, Broderick L. ; Kalman, Douglas ; Kreider, Richard B. ; Gonzalez, Drew E. ; Kerksick, Chad M. ; Arent, Shawn M. ; McAllister, Matthew J. ; Heileson, Jeffery L. ; Gonzalez, Adam M. ; Antonio, Jose ; Roberts, Brandon M. ; Hecht, Karen A. ; Kurtz, Jennifer A. ; Candow, Darren G. ; Stout, Jeffrey R. ; Bloomer, Richard J. ; S. Waldman, Hunter ; Campbell, Bill

Following a comprehensive review, the International Society of Sports Nutrition (ISSN) has developed an official position on the role of dietary antioxidants in exercise and sport. Antioxidants play a complex, context-dependent role in vivo; they can facilitate recovery from exercise but may also hinder training adaptations when consumed at supraphysiological doses. While endogenous antioxidant systems can effectively maintain redox balance, dietary sources, particularly whole foods, can help mitigate excessive oxidative stress following intense/heavy training or inadequate recovery. The influence of dietary antioxidants depend on timing, dosage, type, and individual factors. The ISSN's official position encompasses the following: (1) Redox balance exists on a spectrum, with mild oxidative eustress driving beneficial physiological adaptations and excessive oxidative distress impairing health, recovery, and performance; (2) Moderate levels of exercise-induced reactive oxygen and nitrogen species (ROS/RNS) can support training adaptations but excessive levels can result in muscle damage, inflammation, and reduced physical performance and immune function; (3) Endogenous and exogenous antioxidants protect cells by neutralizing free radicals and reducing oxidative damage to biomolecules; (4) FDA labeling for "antioxidant" claims applies to nutrients with established RDIs and demonstrated antioxidant activity; this typically includes vitamins C and E, β-carotene (a source of vitamin A), selenium, zinc, copper, and manganese; (5) While dietary antioxidants show potential for both direct and indirect effects, the evidence varies, and their use should be tailored to individual performance or recovery goals; (6) Long-term exercise augments endogenous antioxidant defense and should be the primary strategy for enhancing redox capacity before considering supplementation; (7) Whole foods and beverages rich in flavonoids, polyphenols, carotenoids, vitamins, and minerals are preferred antioxidant sources; (8) Dietary supplementation is best reserved for nutrient insufficiencies or deficiencies, inadequate dietary intake, or periods of high training distress; (9) Responses to supplementation vary by individual factors, such as training status, baseline antioxidant capacity, demographics, diet, and injury risk, with some antioxidant compounds offering cognitive, behavioral, or physical-related benefits; and (10) Creatine monohydrate (i.e. 0.1 g/kg/day), omega-3 fatty acids (1000-6000 mg/day EPA+DHA for 6-12 weeks), tart cherry (480 mg powder or 60-90 mL juice/day for 7-14 days), and astaxanthin (4-12 mg/day for 4-12 weeks) rank among the top nutrients for their antioxidant effects, with moderate- to high-quality evidence supporting their use in recovery or performance without interfering with training adaptations. Most others show weak or low efficacy. This position promotes an individualized, evidence-based approach, recognizing that small to moderate exercise-induced oxidative stress aids adaptation, while excess oxidative stress causes harm; it also emphasizes food-forward and dietary supplementation strategies.

2026-12-01·MOLECULAR BIOLOGY REPORTS

Selenium alleviates Staphylococcus aureus-induced mastitis by modulating mitochondrial dynamics and inhibiting the ROS/NLRP3/Pyroptosis pathway

Article

作者: Zhang, Junhao ; Hu, Changmin ; Du, Yanting ; Yang, Jinghan ; Hu, Yanjun ; Qi, Xue ; Jiang, Mingxuan

BACKGROUND:

The pathogenesis of bovine mastitis involves inflammation and cell death, with pyroptosis being a key factor in its development. Currently, antibiotics remain the primary therapeutic option for bovine mastitis, however, the increasing prevalence of antibiotic resistance constitutes a major public health threat. Selenium (Se) has been reported to alleviate inflammation primarily through its antioxidant properties, but the mechanism by which Se regulates pyroptosis in bovine mastitis remains unclear.

METHODS AND RESULTS:

In this study, an in vitro mastitis model was established by infecting MAC-T cells with inactivated Staphylococcus aureus (S. aureus) (MOI = 10, 12 h). The results revealed that the mitochondrial membrane potential of the MAC-T cells in the infection group decreased significantly. Moreover, the accumulation of Reactive oxygen species (ROS) was accompanied by the activation of NOD-like receptor family containing pyrin domain 3 (NLRP3), the expression of the pyroptosis-related genes gasdermin D amino terminal fragment (GSDMD-N), and cysteine aspartate specific protease 1 (cleaved-caspase 1). Pretreatment with Se, the NLRP3 inhibitor MCC950 and the antioxidant N-acetylcysteine (NAC) attenuated mitochondrial damage, ROS accumulation, and the inhibition of pyroptosis. An in vivo mastitis model was established in mice fed a high-selenium diet (containing 1.5 mg/kg Se) and intramammarily injected with inactivated S. aureus (1 × 10⁸ CFU/mL). Histological analysis revealed intact alveolar structure and reduced inflammatory cell infiltration in mice fed the high-selenium diet. The expression of the inflammasome NLRP3 downregulated, and the expression of GSDMD-N, a direct executor of pyroptosis, upregulated.

CONCLUSION:

Our in vitro and in vivo results confirmed that Se alleviate mitochondrial damage and pyroptosis by inhibiting the NLRP3 pathway, ultimately alleviating mastitis.

2026-06-01·Bioactive Materials

A mitochondria-targeted nanoantioxidant restores alveolar bone homeostasis in periodontitis by quenching ROS and suppressing the cGAS-STING pathway

Article

作者: Jiang, Xinquan ; Zheng, Ao ; Wang, Xiao ; Cao, Lingyan ; Huang, Ning ; Xu, Yue ; Pan, Lisha

Prolonged periodontal inflammation and progressive alveolar bone loss are typical manifestations of periodontitis. Antioxidative therapies targeting the central role of reactive oxygen species (ROS) have been explored, but lack of subcellular specificity limits efficacy. Mitochondria function as an upstream redox hub that drives oxidative stress, inflammatory responses, and alveolar bone resorption, making mitochondrial redox modulation a promising yet underexplored strategy for periodontitis therapy. Herein, we developed a mitochondria-targeted, redox-responsive nanocomposite (TC/pSeSe) that enables programmable redox modulation of the pathological periodontal microenvironment. The antioxidative core consists of a ROS-responsive diselenide-containing copolymer (pSeSe) capable of selenium release, while the triphenylphosphine/chitosan (TC) coating confers mitochondrial-targeted, controlled redox activity, mucosal retention and cationic antibacterial properties. With preferential mitochondrial localization, TC/pSeSe undergoes diselenide bond cleavage and selenium release under oxidative stress, thereby restoring mitochondrial redox homeostasis and attenuating downstream mitochondrial DNA (mtDNA)-cGAS-STING-mediated inflammatory signaling. Through combined ROS scavenging and selenium-mediated support, TC/pSeSe mitigates ferroptosis in a partially glutathione peroxidase 4 (GPX4)-dependent manner and restores osteogenic potential in bone marrow-derived stem cells. In parallel, TC/pSeSe exhibits antibacterial activity against periodontal pathogens through combined selenium and the cationic TC coating functionalities. In vivo, TC/pSeSe restored alveolar bone regeneration and attenuated periodontal inflammation. Collectively, this study proposes a mitochondria-centered redox modulation strategy, providing a comprehensive and promising therapeutic approach for periodontitis treatment.

21

项与 Selenium 相关的新闻（医药）

2025-10-27

·EINPresswire

64K Cellssense Featured in Frontiers in Aging for Pioneering Review on Nanoengineered Mitochondria

Company outlines how nanoengineering approaches may advance studies of mitochondrial function and cellular health. This publication in Frontiers in Aging represents a synthesis of emerging data on mitochondrial nanoengineering, reflecting our commitment to peer-reviewed science and measurable longevity research.” — Thomas Miller, Head of the 64K Cellssense International Research Center LAUSANNE, SWITZERLAND, October 27, 2025 / EINPresswire.com / -- 64K Cellssense announced its Research and Innovation Center published a review article in Frontiers in Aging , a leading Swiss academic journal. The article, titled “Nanoengineered Mitochondria for Mitochondrial Dysfunction and Anti-Aging Interventions,” explores the emerging field of mitochondrial nanoengineering and its implications for maintaining cellular function and energy balance. The review provides a comprehensive overview of recent advances in nanoengineered mitochondria — a rapidly growing focus in life sciences. It details how nanoscale design can support mitochondrial integrity, optimize metabolic efficiency, and enhance resilience under cellular stress. The review offers an international perspective on how nanotechnology is shaping next-generation mitochondrial research, reflecting 64K Cellssense’s contribution to the global dialogue on healthy cellular aging. Within 64K Cellssense’s 12-Dimensional Longevity Framework, mitochondrial performance is studied as a core determinant of cellular function. The review proposes a research framework that integrates nanoengineering strategies to optimize mitochondrial energy systems and mitigate oxidative imbalance at the cellular level. The article also summarizes key natural mitochondrial regulators — including α-ketoglutarate (AKG), ergothioneine (EGT), resveratrol, CoQ10, and selenium — and highlights how nano-delivery approaches may improve their stability and targeted bioavailability in experimental models. Building on these foundational insights, 64K Cellssense continues to develop its proprietary MPNutria ® Nano-Nutrition Delivery Technology, based on metal–phenolic network (MPN) nanostructures — a technology lineage related to the 2025 Nobel Prize -winning research on metal-organic frameworks (MOFs). This technology exemplifies how the brand translates cutting-edge scientific concepts into scalable, experimentally validated applications. While mitochondrial nanoengineering shows considerable potential, the review notes that further research is required to address challenges related to delivery consistency, biological compatibility, and scalable production. The Research and Innovation Center of 64K Cellssense has collaborated on projects with academic and clinical partners in Switzerland, the United States, Australia and China, including, among others, ETH Zurich, Harvard University and Clinique Eden Suisse. Collectively, these efforts reinforce 64K Cellssense’s long-term mission to drive data-driven innovation in cellular health, bridging academic research and practical, scalable applications in life sciences. Anastasia Y. Vitagenix Technology Limited email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-03-14

·drugs

Metal Mixtures During Pregnancy May Lower Midlife Hypertension Risk

FRIDAY, March 14, 2025 -- Optimizing copper, manganese, and vitamin B12 during pregnancy can help lower the risk for high blood pressure and hypertension in midlife, according to a study published online March 6 in Hypertension to coincide with the American Heart Association Epidemiology and Prevention/Lifestyle and Cardiometabolic Health 2025 Scientific Sessions, held from March 6 to 9 in New Orleans. Mingyu Zhang, Ph.D., from Harvard Medical School in Boston, and colleagues measured nonessential and essential metals in red blood cells along with folate and vitamin B12 in plasma during pregnancy (participants enrolled 1999 to 2002) to examine long-term associations with midlife blood pressure and hypertension. Midlife blood pressure was measured from 2017 to 2021. A total of 493 women were followed for a median of 18.1 years. The researchers found that a doubling of copper and manganese was associated with 0.75 and 0.80 times the risk for hypertension, respectively, after adjustment. A slightly increased risk for hypertension was seen in association with higher cesium and selenium, but the 95 percent confidence intervals were wide and crossed the null. A doubling of vitamin B12 was associated with 3.64- and 2.52-mm Hg lower systolic and diastolic blood pressure, respectively. There was a monotonic association for the essential metal mixture with lower blood pressure, while threshold effects were seen for its association with hypertension. "These findings suggest that optimizing essential metal levels during pregnancy, particularly, copper and manganese, along with vitamin B12, may offer protective benefits against high blood pressure and hypertension in midlife," the authors write.

AHA会议临床研究

2025-03-07

·drugs

Select Vitamins, Minerals During Pregnancy Protect Heart Health Later

FRIDAY, March 7, 2025 -- Getting essential vitamins and minerals during pregnancy can help a woman maintain healthy blood pressure into middle age, new research suggests. High levels of the minerals copper and manganese in pregnant women were associated with lower blood pressure decades later, as well as a reduced risk of high blood pressure , researchers reported. Higher levels of vitamin B12 also were associated with lower blood pressure in later life, according to findings published March 6 in the journal Hypertension . “Optimizing these essential metals, minerals and vitamins -- particularly copper, manganese and vitamin B12 -- during pregnancy may offer protective benefits against hypertension in midlife, an especially critical time period for women’s future cardiovascular risk in later life,” lead researcher Mingyu Zhang , an epidemiologist at Beth Israel Deaconess Medical Center in Boston, said in a news release. For the study, his team analyzed data from an ongoing long-term study of nearly 500 pregnant women recruited between 1999 and 2002. The women underwent blood testing during their pregnancy for their levels of healthy essential minerals, such as copper, magnesium, manganese, selenium and zinc, researchers said. They also were tested for levels of folate and vitamin B12. After nearly 20 years of follow up, researchers checked in again with the women, who’d now reached an average age of 51. The women’s blood pressure was tested during this check in, and was considered high if greater than 130/80 or if they’d been prescribed high blood pressure meds. Results showed that if women had doubled levels of copper and manganese in their blood during pregnancy, their risk of midlife high blood pressure was 25% and 20% lower, respectively. Doubled levels of vitamin B12 also contributed to lower blood pressure, but researchers noted that about 95% of participants had B12 levels within the normal range. Copper, manganese, selenium and zinc all lowered blood pressure, and the higher the levels, the more blood pressure benefitted later in life, researchers found. However, the findings should not be interpreted as recommendations, since researchers were unable to tell whether women got these vitamins and minerals from food, dietary supplements or other sources, Zhang said. “More research including clinical trials is needed to determine the optimal dietary intake of these minerals and micronutrients,” Zhang said. Researchers hope to ultimately identify women at high risk for developing high blood pressure later in life and intervene during pregnancy, either with enhanced nutrition or supplements. These results were scheduled for presentation Saturday at an American Heart Association meeting in New Orleans. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHA会议临床研究

100 项与 Selenium 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
获得性免疫缺陷综合征	临床3期	巴西	Fundação Oswaldo Cruz	2008-10-31
心脏毒性	临床3期	巴西	Fundação Oswaldo Cruz	2008-10-31
Chagas病	临床3期	巴西	Fundação Oswaldo Cruz	2008-10-31
慢性病	临床3期	巴西	Fundação Oswaldo Cruz	2008-10-31
终末器官损害	临床3期	巴西	Fundação Oswaldo Cruz	2008-10-31
功能障碍	临床3期	巴西	Fundação Oswaldo Cruz	2008-10-31
亨廷顿舞蹈病	临床3期	巴西	Fundação Oswaldo Cruz	2008-10-31
梗塞	临床3期	巴西	Fundação Oswaldo Cruz	2008-10-31
克山病	临床3期	巴西	Fundação Oswaldo Cruz	2008-10-31
心肌梗塞	临床3期	巴西	Fundação Oswaldo Cruz	2008-10-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01611896 (GRASS, Pubmed \| Eur Thyroid J)	N/A	格雷夫斯病	430	Selenium supplementation	築艱糧選餘選壓鬱淵艱(網簾窪簾糧構繭廠鏇淵) = 鏇蓋醖選積醖鹽窪蓋鑰鏇選餘獵願積膚壓鹽窪 (鏇壓網艱繭壓獵艱衊淵 )	不佳	2025-12-12
				Placebo	築艱糧選餘選壓鬱淵艱(網簾窪簾糧構繭廠鏇淵) = 選願膚簾顧鑰遞獵鹹觸鏇選餘獵願積膚壓鹽窪 (鏇壓網艱繭壓獵艱衊淵 )
AACR2018	临床1期	女性生殖器官肿瘤	-	Selenious acid/carboplatin/paclitaxel	獵壓觸選壓憲衊範糧憲(廠構艱獵窪繭築蓋顧簾) = 壓築窪鹹築鏇鏇糧窪艱廠糧膚鏇顧襯構齋淵糧 (壓範壓憲觸憲窪廠製積 ) 更多	-	2018-07-01
ASCO2014	N/A	第二原发肿瘤	-	Selenium	艱艱願衊艱醖衊獵顧廠(廠齋夢襯簾衊網淵鏇築) = 壓鹹繭網積鏇艱網鏇廠顧襯窪網糧齋齋憲網鑰 (糧簾網襯範築餘鑰鹹鑰, 0.77 ~ 2.38)	-	2014-05-20
				Placebo	艱艱願衊艱醖衊獵顧廠(廠齋夢襯簾衊網淵鏇築) = 範範顧窪糧鑰艱網淵觸顧襯窪網糧齋齋憲網鑰 (糧簾網襯範築餘鑰鹹鑰 )
Pubmed \| Cochrane Database Syst Rev	N/A	桥本病	463	Selenium supplementation	鑰夢簾艱獵繭齋艱鹹壓(簾築餘鬱願願構餘醖蓋): RR = 4.67 (95% CI, 1.61 ~ 13.5), P-Value = 0.004	-	2013-06-06
				Selenium
ASCO 12010 \| ASCO 22010	临床3期	非小细胞肺癌Ⅰ期	-	selenium (Se) supplementation (Selenized yeast 200 micrograms)	糧鬱膚網衊選夢製築顧(繭齋鹽蓋範願襯鹽顧觸) = 艱製壓鬱積膚願製壓鏇鑰鏇齋積獵鹹積範構鏇 (簾鑰範繭遞醖構觸鏇壓 ) 更多	不佳	2010-06-20
				Placebo	糧鬱膚網衊選夢製築顧(繭齋鹽蓋範願襯鹽顧觸) = 憲襯範膚淵製鹽簾繭觸鑰鏇齋積獵鹹積範構鏇 (簾鑰範繭遞醖構觸鏇壓 ) 更多
German Working Group on Trace Elements and Electrolytes (ASTRO2009)	临床2期	头颈部肿瘤 selenium deficiency	40	Selenium supplementation	網夢顧構餘窪繭獵觸鬱(廠遞觸積淵鏇廠蓋遞鹹) = 壓獵醖鏇觸憲簾衊繭鏇築齋選繭窪鹹鹹願醖醖 (願繭築選積鑰鹽範築膚 ) 更多	不佳	2009-11-01
				Control group (no selenium supplementation)	網夢顧構餘窪繭獵觸鬱(廠遞觸積淵鏇廠蓋遞鹹) = 構糧餘選艱鏇糧壓廠膚築齋選繭窪鹹鹹願醖醖 (願繭築選積鑰鹽範築膚 ) 更多
ASCO2009	临床2期	头颈部肿瘤	39	selenium (Group A)	範選憲範淵艱網築築鹹(壓觸繭構醖醖鑰壓廠艱) = 築構夢觸選顧艱觸網憲觸蓋齋簾鬱鹽醖膚願選 (獵廠艱窪選膚窪積願構 ) 更多	不佳	2009-05-20
				selenium (Group B)	範選憲範淵艱網築築鹹(壓觸繭構醖醖鑰壓廠艱) = 顧衊齋遞觸構窪鏇醖築觸蓋齋簾鬱鹽醖膚願選 (獵廠艱窪選膚窪積願構 ) 更多
ASCO2008	临床2期	前列腺癌	140	Placebo	廠鑰製衊築廠鹹積夢顧(齋鏇膚艱醖壓鑰網蓋蓋) = 壓淵窪鹽夢膚襯鏇蓋範膚鏇壓範鹹顧鏇構簾鑰 (衊艱製淵築構膚願觸糧 )	不佳	2008-05-20
				200µg/day Selenium	廠鑰製衊築廠鹹積夢顧(齋鏇膚艱醖壓鑰網蓋蓋) = 壓醖範淵鏇範蓋醖積鹽膚鏇壓範鹹顧鏇構簾鑰 (衊艱製淵築構膚願觸糧 )